Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Aegirbio receives an Intention to Grant from the European Patent Office

Aegirbio AB (“Aegirbio”) has received an Intention to Grant notice from the European Patent Office (“EPO”) for its patent application for the quantitative, point-of-care and point-of-need, thyroid hormones test product (Thyrolytics). In essence, this means that the EPO intends to approve the company’s application.The patent application, with application number PCT/EP2019/068869, for which the EPO has issued an Intention to Grant notice, refers to the Thyrolytics’ biosensor product for use in detecting and quantifying the thyroid hormones T3 and T4 using a capillary blood sample. The patent

Change in number of shares and votes in BONESUPPORT Holding AB (publ)

Lund, Sweden, 12:00 CET, 30 June 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During June, the number of shares and votes in BONESUPPORT Holding AB (publ) has increased with 362,096 due to the exercise of warrants.   As of 30 June 2021, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 65,430,318 shares, of which 64,140,318 are ordinary shares with one vote per share and 1,290,000 are series C-shares with one-tenth of a vote per share. The number

Announcement from Nilar's annual general meeting

The annual general meeting of Nilar International AB ("Nilar" or the "Company") was held today on 30 June 2021 and the following resolutions were passed by the meeting. ADOPTION OF THE INCOME STATEMENT AND BALANCE SHEET The annual general meeting resolved to adopt Nilar's income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. DISTRIBUTION OF PROFIT The annual general meeting resolved to treat the result in accordance with the proposal of the board of directors in the annual report, meaning that the result is carried

Semcon accelerates its climate action agenda – commits to several initiatives and the 1.5 °C ambition

International technology company Semcon joins the Exponential Roadmap Initiative, the Science Based Targets initiative, the Race to Zero campaign and the UN Global Compact. These initiatives are all aligned with the ambition of the Paris Agreement to limit the global warming to 1.5 °C above pre-industrial levels.By joining these initiatives, Semcon will further integrate practices that align with the 1.5 °C ambition into the company’s daily work. With more than 2,000 employees in seven countries supporting customers in various industries, this step will have an impact that extends far

Qred hires CPO from Klarna

Swedish fintech company Qred strengthens the management team and recruits a new Chief Product Officer (CPO). Marcus Uggla, who most recently worked at Klarna where he was a Senior Product Manager, joined Qred in June. Stockholm, 30 June, 2021 - Qred, one of Sweden’s fastest growing companies, has during the past year hired more than 70 people. Now, the fintech company strengthens the management team with a new CPO; Marcus Uggla. Uggla, who most recently worked at  Klarna, will lead Qred’s product team. The team will in the near future focus on Qred’s recently launched credit card

Aptahem receives Notice of Allowance from the US Patent Office for the protection of patent family 2

Aptahem AB (publ) announces today that the company has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance fo the US patent application 16/652,926 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties. The application covers the therapeutic protection of the company’s aptamer Apta-1 which is being developed as treatment for disease syndroms caused by inflammation, coagulation and/or organ failure.This application is part of the patent family 2 with Aptahem’s CSO Dr Luiza Jedlina

Acquisition: Sitowise and Enco wish to bring property management into a new era

Sitowise Group Plc                            Media Release                              30 June 2021 at 12:45 p.m.Sitowise has acquired property management expert Enco Oy, a company providing consulting services related to property management and maintenance. Together, the companies want to challenge the old practices of property maintenance consulting. – We urge to start the new era of knowledge-based property management. We are the perfect team for this task, as we combine Sitowise's digital expertise with Enco's strong data management knowhow in the real estate sector, says

Annual Financial Report

Investec Bank plcIncorporated in England and WalesRegistration number 489604           Investec Bank plc (the "Company") Annual Report and Financial Statements   In compliance with the Listing Rules of the United Kingdom Listing Authority (the "UKLA"), the Company's Annual Report and Financial Statements for the year ended 31 March 2021 (the "Annual Report and Financial Statements") have been issued today and can be viewed on the Company's website: www.investec.com/annualreports   A copy of the Annual Report and Financial Statements will be submitted to

Invitation to Saab’s Interim Report Q2 2021 Presentation

Saab’s CEO and President Micael Johansson and CFO and deputy CEO Christian Luiga will present the Saab interim report for January-June 2021.Date:            Wednesday, 21 July at 10:00 (CET). The report is published at 07.30 a.m. (CET) the same day at http://www.saab.com.  You are welcome to watch the live webcast or dial in to the conference call. It is possible to post questions over the conference call and the web.  Live webcast: http://saab-interimreport.creo.se/210721 Conference call: Please, dial in using one of the numbers below. Sweden (Sverige):

Mentice receives order of total SEK 5.9 million from Baylis Medical Company

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on interventional procedures, has entered into an agreement with Baylis Medical Company (“Baylis”) to provide simulation solutions. Based on this order, Mentice will support Baylis’ product portfolio for transseptal puncture procedures with Mentice systems to be delivered in the second and third quarter of 2021. The systems are based on the Mentice’ VIST G5 platform and will support Baylis commercialization efforts to launch new medical devices in a safe and effective way

Bong increase prices to the market

Bong has decided to increase its prices to the market as a result of the continued increase in raw material prices. The majority of Bong’s price increases will come into effect during Q3 2021 and will be on both Envelope and Light packaging products. Reason behind this is that most of Bong’s raw materials such as paper, window film, ink, adhesives, plastics etc. have recently seen drastic price increases.  Especially drastic and still ongoing in the coming months are the large price increases on paper which were triggered by historically high pulp cost in combination with a strong

Completion of the offering and registration of capital increase in Aquaporin A/S

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFULThis announcement does not constitute a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017 and nothing herein shall be construed as an offering of securities. No one should purchase or subscribe for any securities in Aquaporin A/S except on the basis of information in the prospectus published by Aquaporin A/S in connection with

Eco Wave Power Wins a Third Grant During the Month of June

30/06/2021- Stockholm, Sweden — Eco Wave Power Gibraltar, a subsidiary of leading global wave energy developer Eco Wave Power (Eco Wave Power Global, Ticker Symbol: ECOWVE) is pleased to announce the approval of a grant project budget of 296,787 GBP (approx. SEK 3,508,734) by Innovate UK - the UK’s innovation agency. The grant is provided as part of the Energy Catalyst Round 8: clean energy- experimental development competition, for a project titled “Sea Wave Energy Powered Microgrid for Remote Islands and Rural Coasts”, to be executed in collaboration with the UK Queen Mary

Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B): During June, shareholders exercised 89,090 warrants (TO4B). The number of shares has increased by 89,090 B-shares during the subscription period, and the number of votes has increased by 89,090. The number of warrants remaining for future subscription periods is 1,416,386. The terms of the warrants are published on Episurf Medical's website. The total number of shares amounts to 222,129,633, 951,020 are A-shares, and 221,178,613 are B-shares. The total number of votes after the conversions amounts to 224,031,673.

Conversion of shares in NCC AB

According to NCC’s articles of association, owners of Series A shares are entitled to request that such shares be converted to Series B shares. Conversion reduces the total number of voting rights in the company.During June 2021, 52,110 Series A shares were converted to Series B shares at the request of shareholders, following which the total number of voting rights in the company amounts to 224,662,929. The total number of registered shares in the company amount to 108,435,822, of which 12,914,123 are Series A and 95,521,699 are Series B.  NCC holds 841,072 Series B shares in treasury.

Reduced number of shares and votes in ABB Ltd

Zurich, Switzerland, June 30, 2021Based on the capital reduction approved at the Annual General Meeting on March 25, 2021 and following the required waiting period, 115,000,000 shares of ABB Ltd repurchased under a share buyback program were cancelled earlier this month. The total number of ABB Ltd’s issued shares and votes is 2,053,148,264, compared with 2,168,148,264 before the cancellation. As of yesterday, the company’s holding of its own shares amounted to 47,154,315 which corresponds to 2.3 percent of the total number of issued shares in the company. This includes 28,339,689

Change in number of shares and votes in RVRC Holding AB (publ)

In connection with the listing of RVRC Holding AB (publ) (the “Company”) on Nasdaq Stockholm on 16 June 2021 subscription warrants of series (I)–(III)(A)–(G) were exercised for subscription of new shares in the Company (the “Exercise”). Through the Exercise, the Company has received approximately MSEK 46.8 as subscription payment. As a result of the Exercise, the Company’s share capital has increased by SEK 51,714.69 and the number of shares and votes has increased with 5,171,469 shares and votes during June 2021. As per 30 June 2021, the Company’s share capital amounts to SEK 1,129,189.

FluoGuide enters agreement with Swedish university hospital for the second phase of the ongoing FG001 clinical trial (correction)

Correction: The subject line in e-mail recipients contained a wrong text. No other corrections. Copenhagen, Denmark, 30 June 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the Company has entered into an agreement with the Department of Neurosurgery, Linköping University Hospital, Sweden to become the second site investigating FG001´s effect in guiding surgical removal of aggressive brain cancer. Linköping University Hospital is added to the second phase of the ongoing clinical phase I/II trial.The ongoing clinical phase I/II trial with FG001 is designed

Vestas and Iberdrola finalise contract on Baltic Eagle offshore project in Germany

News release fromVestas Northern and Central EuropeHamburg, 30 June 2021 Vestas and Iberdrola have finalised the turbine supply contract for the Baltic Eagle project being developed off the island of Rügen, in German waters of the Baltic Sea. Vestas will deliver V174-9.5 MW turbines to the 476 MW Baltic Eagle project, which will span a 40 km[2] area in the Baltic Sea and is located 75 km off the German coast. Baltic Eagle is Vestas’ fourth offshore project in Germany, adding to the Borkum Riffgrund 2 and Deutsche Bucht projects which were delivered by the joint venture MHI Vestas

Veg of Lund’s launches its plant-based drink DUG in China

Veg of Lund takes another step in the launch of its new plant-based beverage, DUG[®], this time through the Chinese food chain Ole’ Supermarket. The introduction takes place in about ten stores in Shanghai and Shenzhen, two cities with a total of 40 million inhabitants. In parallel, Ole’ is launching DUG on its e-commerce platform to its more than two million online followers.DUG is an alternative to animal milk and other plant-based drinks and meets consumers’ demand for plant-based foods that are good from a taste, health and climate perspective. Sales of DUG[®] are underway in Sweden and

Half the Nation Avoiding Their Veggies

Veganize Your Summer BBQ with Madeleine Shaw and ReadlyWith more of us than ever staying mindful of what we put into our bodies and the environment, 7.2 million Brits (14 percent) are now eating vegetarian or vegan food every day. However, despite the well-known benefits of eating a plant-based diet - it continues to remain a mystery for many. More than 8.2 million (16 percent) of the nation do not know what a vegan meal is, according to the latest research commissioned by Readly. Digital magazine and newspaper subscription service Readly , worked with YouGov

FluoGuide enters agreement with Swedish university hospital for the second phase of the ongoing FG001 clinical trial

Copenhagen, Denmark, 30 June 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the Company has entered into an agreement with the Department of Neurosurgery, Linköping University Hospital, Sweden to become the second site investigating FG001´s effect in guiding surgical removal of aggressive brain cancer. Linköping University Hospital is added to the second phase of the ongoing clinical phase I/II trial.The ongoing clinical phase I/II trial with FG001 is designed as a two-phase trial, where the first phase aims to identify the optimal dose and investigate

New acting managing director of capital market at SpareBank 1 Nord-Norge

Jon Christoffersen (40) has been appointed acting director of SNN Kapitalmarked, the bank's department for investment services for both the private and corporate markets. He will take over the job on September 1, when current director Tom Robin Solstad-Nøis starts his new job at Coop Nord.  Christoffersen has a master's degree in economics and administration from UiT Norway's Arctic University. He has worked at SpareBank 1 Nord-Norge since 2008, both as a senior intrest rate broker and senior portfolio manager.   Contact persons at SpareBank 1 Nord-Norge:  · Liv B. Ulriksen, CEO,

Cline Scientific AB will present in a live event on the Facebook group Aktietips

Cline Scientific AB will participate in a live streamed presentation event on the Facebook group Aktietips. There will be a company presentation followed by a Q&A with CEO Patrik Sundh.Date: Thursday 1st July Time: 19:00 The presentation will be available afterwards on Aktietips YouTube channelhttps://www.youtube.com/channel/UCejOGGgGL9eWJtQmUzjFWrw     For more information, please contact:  Patrik Sundh, CEOEmail: patrik.sundh@clinescientific.comPhone: +46 703-585 088

There are no items matching the current filter
There are no more items matching the current filter
Back to top